Early and continued asthma control improvement in patients with severe eosinophilic asthma (SEA) over 1 year post benralizumab initiation: real-world XALOC-2 programme

<bold>Background:</bold> Benralizumab depletes blood eosinophils in <24 hrs and may lead to rapid improvements in patients (pts) with SEA. <bold>Aim:</bold> To understand the real-world effectiveness of benralizumab on asthma symptom control from 1 to 56 weeks (Wk) post initiation. <bold>Methods:</bold> XALOC-2 comprises prospective, real-world studies (Belgium, Canada, Germany and Switzerland) of benralizumab in pts with SEA. This 56-Wk integrated analysis assessed longitudinal changes in ACQ score. <bold>Results:</bold> Of 535 pts (median age: 58 yrs; 49% female) mean (SD) ACQ score at baseline (BL) was 3.0 (1.2) decreasing to 1.5 (1.2) by Wk 56. The greatest improvement in ACQ score occurred between BL and Wk 1 and further improved up to Wk 56 (Fig 1A). Clinically meaningful improvements (minimal clinically-important difference [MCID] threshold=‒0.5) were seen in 58% of pts (282/486) at Wk 1. At Wk 56, 79% (276/351) had an improvement ≥1xMCID, and 62% (218/351) ≥2xMCID. Significantly improved asthma control was seen across all clinically relevant BL characteristic subgroups (Fig 1B). <bold>Conclusions:</bold> Clinically meaningful improvements in asthma symptom control began from 1 Wk post benralizumab initiation or earlier and further improved over 1 yr. Benefits were seen in the overall population and were consistent across key subgroups important to therapeutic decision-making in daily practice. <fig><object-id>erj;64/suppl_68/PA5358/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig>